Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TAK-491 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| TAK-491 40 mg (Open Label) | EXPERIMENTAL | TAK-491 40 milligram (mg), tablet, orally, once daily on Day 1 and Days 4 to 10 as an open-label treatment. |
| TAK-491 80 mg (Open-label) | EXPERIMENTAL | TAK-491 80 mg, tablet, orally, once daily on Day 1 and Days 4 to 10 as an open-label treatment. |
| TAK-491 40 mg (Double-blind) | EXPERIMENTAL | TAK-491 40 mg, tablet, orally, once daily and TAK-491 80 mg placebo-matching tablet, orally, once daily on Day 1 and Days 4 to 10 in double-blind manner. |
| TAK-491 80 mg (Double-blind) | EXPERIMENTAL | TAK-491 80 mg, tablet, orally, once daily and TAK-491 40 mg placebo-matching tablet, orally, once daily on Day 1 and Days 4 to 10 in double-blind manner. |
| Placebo | PLACEBO_COMPARATOR | TAK-491 40 mg placebo-matching tablet, orally, once daily and TAK-491 80 mg placebo-matching tablet, orally, once daily on Day 1 and Days 4 to 10. |
| Name | Type | Description |
|---|---|---|
| TAK-491 | DRUG | TAK-491 tablets |
| TAK-491 placebo | DRUG | TAK-491 placebo-matching tablets |
Inclusion Criteria: 1. Is capable of understanding and complying with protocol requirements. 2. The participant or, when applicable, the legally acceptable representative signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study pro...
TAK-491 is an investigational small molecule being studied in healthy volunteers. It is currently in Phase 1 clinical development, with a completed trial evaluating its pharmacokinetics in healthy Chinese participants. TAK-491 is not approved for any indication and remains under clinical investigation.
TAK-491 is being developed by Takeda Pharmaceutical Company Limited, which trades under the ticker TAK. The company is conducting clinical trials to evaluate the drug's pharmacokinetics in healthy volunteers.
TAK-491 is in Phase 1 clinical development. A Phase 1 trial has been completed, and the drug is not yet approved. It remains investigational and is being studied in healthy volunteers to assess its pharmacokinetics.
TAK-491 has one completed Phase 1 trial, NCT02541669, titled 'A Single- and Multiple-Dose Study of the Pharmacokinetics of TAK-491 in Healthy Chinese Participants.' The trial enrolled 64 participants in China and was randomized, double-blind, and placebo-controlled.
TAK-491 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The completed trial, NCT02541669, was a pharmacokinetic study in healthy volunteers, and the drug has not yet progressed to later-stage trials or regulatory approval.